

# ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

## Scientific Program

---

### Saturday June 10, 2023

Optional excursions

15:00 Registration

Opening Session

17:30 **Opening of the Symposium and Welcome address**  
Prof. Daniel HARKI  
(UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States)

17:45 **PL01- Medicinal Chemistry, Trends, Targets and Technologies**  
Dr Klaus URBAHNS  
(MERCK KGAA, Darmstadt, Germany)

18:30 **Welcome Reception**

## Scientific Program

**Sunday June 11, 2023**

**08:00 Registration**

### Session 1 - Chemical Modulation of RNA

#### Session chair

Dr Darby SCHMIDT  
(SONATA THERAPEUTICS, Cambridge, United States)

**09:00 IL01 - Modulating the Conformation and Function of Disease-Relevant RNA with Small Molecules**

Prof. Amanda HARGROVE  
(DUKE UNIVERSITY, Durham, NC, United States)

**09:30 IL02 - Targeting Non-Coding RNAs Using Synthetic Small Molecules: Original Targets for Innovative Therapies**

Dr Maria DUCA  
(UNIVERSITY OF CÔTE D'AZUR, Nice, France)

**10:00 IL03 - Discovery and Development of Selective Splicing Modifiers as Therapeutics**

Dr Matthew WOLL  
(PTC THERAPEUTICS, South Plainfield, NJ, United States)

**10:15 OC01**

**10:30 Coffee break & Exhibition**

### Session 2 - Advances in Targeted Protein Degradation

#### Session chair

Prof. Terry MOORE  
(UNIVERSITY OF ILLINOIS, Chicago, IL, United States)

**11:00 IL04 - Ligand Directed Degradation: from Proof-of-Concept Degradation to Clinical Studies**

Dr Deborah MORTENSEN  
(BRISTOL MYERS SQUIBB, San Diego, CA, United States)

**11:30 IL05 - Chemical Biology Studies of the Thalidomide-Binding Domain of Cereblon**

Prof. Christina WOO  
(HARVARD UNIVERSITY, Cambridge, MA, United States)

**12:00 OC02**

**12:15 OC03**

**12:30 Lunch & Exhibition**

## Scientific Program

### Session 3 - Proximity-inducing Molecules and their Therapeutic Applications

#### Session chair

Dr Amit CHOUDHARY  
(THE BROAD INSTITUTE, Cambridge, MA, United States)

**14:00 IL06 -Chemoproteomic-Enabled Development of Proximity-Inducing Molecules**

Dr Christopher PARKER  
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

**14:30 IL07 - An Intramolecular Bivalent Degradator Glues an Intrinsic BRD4-DCAF16 Interaction**

Prof. Alessio CIULLI  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

**15:00 OC04**

**15:15 OC05**

**15:30 Coffee break & Exhibition**

**16:00 PL02 - RIPTACs: A New 'Hold and Kill'-based Therapeutic Modality**

Prof. Craig CREWS  
(YALE UNIVERSITY, New Haven, CT, United States)

**16:45 Poster session 1 (odd numbers)**

**18:00 End of the day**

## Scientific Program

### Monday June 12, 2023

#### Session 4 - Drug Targets in GPCR Signaling

##### Session chair

Prof. György KESERU  
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

**09:00 IL08 - New Hot Targets? Medicinal Chemistry of G Protein-Coupled Receptors Involved in Immunity and Cancer**

Prof. Christa MÜLLER  
(UNIVERSITY OF BONN, Bonn, Germany)

**09:30 IL09 - Frontier SBDD across the Orthosteric and Allosteric GPCRome**

Dr Chris DE GRAAF  
(SOSEI HEPTARES, Cambridge, United Kingdom)

**10:00 OC06**

**10:15 OC07**

**10:30 Coffee break & Exhibition**

#### Session 5 - Organic Synthesis Impacting Medicinal Chemistry & Chemical Biology

##### Session chair

Prof. Rui MOREIRA  
(UNIVERSITY OF LISBON, Lisbon, Portugal)

**11:00 IL10 - Photocatalysis in the Pharmaceutical Industry: Synthesis under a New Light**

Dr Giulia BERGONZINI  
(ASTRAZENECA, Gothenburg, Sweden)

**11:30 IL11 - HTE Chemistry to Accelerate Medicinal Chemistry Programs**

Dr Fabio LIMA  
(NOVARTIS, Basel, Switzerland)

**12:00 OC08**

**12:15 OC09**

**12:30 Lunch & Exhibition**

#### Session 6 - Enabling Chemistries for Chemical Biology Research

##### Session chair

# ACSMEDI-EFMC Medicinal Chemistry Frontiers 2023

## Scientific Program

Prof. Daniel HARKI  
(UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States)

**14:00 IL12 - Chemical Probes Enabling Drug Target Discovery and Validation**

Prof. Edward TATE  
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

**14:30 IL13 - Generating Stem-Like T Cells with Small-Molecule Modulators for Cancer Immunotherapy**

Prof. Peng WU  
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA, United States)

**15:00 OC10**

**15:15 OC11**

**15:30 Coffee break & Exhibition**

**16:00 PL03 -Carbohydrates in Health and Disease**

Prof. Laura KIESSLING  
(MIT, Cambridge, MA, United States)

**16:45 Poster session 2 (even numbers)**

**Tuesday June 13, 2023**

### Session 7 - A Focus on Early Career Investigators

#### Session chair

Dr Melissa GRENIER-DAVIES  
(GLAXOSMITHKLINE, Cambridge, MA, United States)

**09:00 IL14 - E3 Ligase Ligand Discovery for TPD**

Dr Benika PINCH  
(NOVARTIS, Cambridge, MA, United States)

**09:15 IL15 - Chemical Approaches to Enhance Cellular Immunotherapies**

Dr Mark P. FARRELL  
(UNIVERSITY OF KANSAS, Lawrence, KS, United States)

**09:30 IL16 - Machine Learning Tools to Accelerate Chemical Biology Studies**

Dr Tiago RODRIGUES  
(UNIVERSITY OF LISBON, Lisbon, Portugal)

**09:45 OC12**

**10:00 OC13**

**10:15 OC14**

**10:30 Coffee break & Exhibition**

### Session 8 - Approaches to Identify and Target Cryptic and Allosteric Pocket

#### Session chair

Dr Malin LEMURELL  
(ASTRAZENECA, Gothenburg, Sweden)

**11:00 IL17 - A Computation-First Approach to Drug Challenging Disease Targets**

Dr Woody SHERMAN  
(PSIVANT THERAPEUTICS, Boston, MA, United States)

**11:30 IL18 - X-ray Crystallographic Fragment Screening for the Identification of Allosteric binding Sites**

Dr Andrew WOODHEAD  
(ASTEX THERAPEUTICS, Cambridge, United Kingdom)

**12:00 OC15**

**12:15 OC16**

**12:30 Lunch & Exhibition**

### Session 9 - Getting Out of the Starting Block: New Hit Finding and Chemotype Advancement Methods

#### Session chair

Dr Carolyn DZIERBA  
(BRISTOL-MYERS SQUIBB, Cambridge, United States)

- 14:00**    **IL19 - RAPID – a Next-Generation Chemoproteomics Technology Enabling the Discovery of Reversible Binders to Pre-specified Targets in Living Cells**  
Dr Justin RETTENMAIER  
(JNANA THERAPEUTICS, Boston, MA, United States)
- 14:30**    **IL20 - Covalent Fragment-Based Drug Discovery**  
Dr Daniel ERLANSON  
(FRONTIER MEDICINES, South San Francisco, CA, United States)
- 15:00**    **IL21 - Large-scale in Silico Fragment Screening of ~200 Million Fragments Based on Absolute Free Energy Perturbation**  
Dr Eric THERRIEN  
(SCHRODINGER, New York, NY, United States)
- 15:15**    **OC17**
- 16:00**    **End of the Symposium**